Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has shared an announcement.
EBR Systems, Inc. announced significant advancements with the FDA approval of its WiSE CRT System, a groundbreaking leadless cardiac pacing technology. This approval, alongside acceptance into the CMS’ TCET pathway and proposed NTAP reimbursement, enhances EBR’s market positioning and operational capabilities. The company also expanded its manufacturing capacity with a new facility lease, supporting its strategic commercialization plans and anticipated market demand.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
EBR Systems, Inc. is a developer in the medical technology industry, specializing in wireless cardiac pacing devices for heart failure. The company focuses on innovative solutions like the WiSE CRT System, which is the world’s first leadless solution for left ventricular endocardial pacing, addressing unmet clinical needs for heart failure patients.
Average Trading Volume: 913,343
For a thorough assessment of EBR stock, go to TipRanks’ Stock Analysis page.